These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 12494781)

  • 1. [Dyslipidemias and cardiovascular diseases: towards a new perspective].
    Darioli R; Depairon M; Perdrix J; Mooser V
    Rev Med Suisse Romande; 2002 Oct; 122(10):489-93. PubMed ID: 12494781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
    Fazio S
    Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dyslipidemias and the primary prevention of cardiovascular disease: analysis of the FAMUS primary care register.
    Xhignesse M; Laplante P; Niyonsenga T; Courteau J; Grant AM
    Can J Cardiol; 2000 Jul; 16(7):879-85. PubMed ID: 10934306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
    Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
    Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth in use of lipid-lowering therapies: are we targeting the right patients?
    Dubois RW; Alexander CM; Wade S; Mosso A; Markson L; Lu JD; Nag S; Berger ML
    Am J Manag Care; 2002 Oct; 8(10):862-7. PubMed ID: 12395954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Dyslipidemias in the elderly].
    Schils E
    Rev Med Brux; 2001 Sep; 22(4):A338-40. PubMed ID: 11680198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary prevention trials: lessons learned about treating high-risk patients with dyslipidemia without known cardiovascular disease.
    Ferdinand KC
    Curr Med Res Opin; 2005 Jul; 21(7):1091-7. PubMed ID: 16004678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statins and diabetes.
    Carmena R; Betteridge DJ
    Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.
    Jones PH
    Am J Cardiol; 2008 Dec; 102(12A):41L-47L. PubMed ID: 19084089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical practice guidelines for the management of dyslipidemia.
    Nichols N
    Can J Cardiovasc Nurs; 2004; 14(2):7-10. PubMed ID: 15230023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Lipid lowering treatment of patients with atherosclerotic disease of the lower extremities].
    Bismuth J; Kofoed SC; Sillesen HH
    Ugeskr Laeger; 2001 Dec; 163(49):6882-5. PubMed ID: 11766498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
    Mullins CD; Rattinger GB; Kuznik A; Koren MJ
    Clin Ther; 2008; 30 Pt 2():2204-16. PubMed ID: 19281915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of hyperlipidemia: new LDL-C targets for persons at high-risk for cardiovascular events.
    Balbisi EA
    Med Sci Monit; 2006 Feb; 12(2):RA34-9. PubMed ID: 16449961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease.
    Staels B; Maes M; Zambon A
    Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):542-53. PubMed ID: 18628776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid-lowering therapy in patients with type 2 diabetes: the case for early intervention.
    Steinmetz A
    Diabetes Metab Res Rev; 2008; 24(4):286-93. PubMed ID: 18273835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increase in lipid-lowering treatment rates among TRICARE beneficiaries: a population-based study.
    Devine J; Linton A; Mistry H; Napier J; Trice S; Bacon T
    Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):891-9. PubMed ID: 19634117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging non-statin LDL-lowering therapies for dyslipidemia and atherosclerosis.
    Shah PK
    Rev Cardiovasc Med; 2003; 4(3):136-41. PubMed ID: 12949442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
    Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Dyslipidemia and global cardiovascular risk: treatment guidelines].
    Vigna GB; Fellin R
    Ital Heart J; 2003 Dec; 4 Suppl 7():4S-12S. PubMed ID: 14983742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Lipid anomalies during renal insufficiency: consequences on the progression of renal insufficiency and cardiovascular risk].
    Moulin B
    Nephrologie; 2000; 21(7):339-41. PubMed ID: 11200605
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.